Key Points
-
CRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY.
-
Vertex Pharmaceuticals maintains a dominant, highly profitable position in the global cystic fibrosis market.
-
Which biotechnology stock offers the best balance of clinical potential and financial stability for your portfolio?
- 10 stocks we like better than CRISPR Therapeutics ›
Choosing between the cutting-edge potential of CRISPR Therapeutics (NASDAQ:CRSP) and the established commercial success of Vertex Pharmaceuticals (NASDAQ:VRTX) is a classic debate for biotech investors. Both companies are currently shaping the future of medicine through gene-based therapies.
CRISPR Therapeutics is a younger, research-focused pioneer that recently achieved its first product approval. Vertex is a cash-generating giant that provides the commercial muscle and funding for their shared lead program. Comparing these two reveals very different approaches to the high-stakes world of modern medicine.
The case for CRISPR Therapeutics
CRISPR Therapeutics focuses on developing transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. Its primary business strategy involves collaborating with larger partners to bring complex treatments like CASGEVY to patients with sickle cell disease and transfusion-dependent beta thalassemia. This helps the company manage the high costs of biotech stocks that are moving from research to commercialization.
In its latest annual report, filed for FY 2025, revenue reached nearly $3.5 million, which represented a 90% decrease from the prior year. This drop occurred because revenue in earlier periods was driven by large one-time milestone payments from partners rather than recurring sales. Consequently, the company reported a net loss of approximately $581.6 million for the year as it continued to invest heavily in its research pipeline.
As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.2x. This ratio measures total debt against the value of what shareholders own, suggesting the company maintains a conservative debt level. The current ratio, which shows the ability to pay short-term debts with short-term assets, was roughly 13.3x. Free cash flow, the cash left after paying for operations and equipment, was a negative $345.9 million.
The case for Vertex Pharmaceuticals
Vertex Pharmaceuticals is the world leader in treating cystic fibrosis, which provides a massive and stable revenue stream for the company. It sells its medicines primarily to specialty pharmacies and distributors globally, as well as major wholesalers in the U.S. This core business allows Vertex to fund ambitious expansions into acute pain, kidney disease, and its gene-editing partnership with CRISPR Therapeutics.
In FY 2025, revenue reached nearly $12.1 billion, representing an increase of roughly 9.6% year-over-year. The company reported a healthy net margin of approximately 32.7%, which measures the percentage of revenue remaining as profit after all expenses are paid. This high profitability highlights the company’s ability to generate significant earnings from its specialized portfolio of treatments.
As of its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.2x. This indicates that the company carries very little debt compared to its total shareholder equity. The current ratio was nearly 2.9x, which indicates a strong ability to cover near-term financial obligations. Free cash flow was close to $3.2 billion, providing the company with plenty of cash for potential acquisitions or internal research projects.
Risk profile comparison
CRISPR Therapeutics faces significant ongoing operating losses and there is no guarantee it will achieve future profitability. The company relies heavily on Vertex for the commercial success and manufacturing of CASGEVY, and it may need to raise more capital, which could dilute existing shareholders. Additionally, it is involved in a patent infringement lawsuit initiated by ToolGen in late 2025 regarding its core gene-editing technology.
Vertex Pharmaceuticals deals with substantial revenue concentration, as most of its sales come from its cystic fibrosis medicines. The company also faces pressure from global drug pricing and cost-containment initiatives, such as state-level affordability boards in the U.S. It also manages complex manufacturing requirements for its new cell therapies and faces potential royalty disputes. To diversify, it maintains strategic collaborations with partners like Zai Lab (NASDAQ:ZLAB) for Asian markets.
Valuation comparison
Vertex Pharmaceuticals appears more established with a lower sales multiple, while CRISPR Therapeutics shows a lower price relative to its future earnings estimates.
MetricCRISPR TherapeuticsVertex PharmaceuticalsForward P/EN/A39.9xP/S ratio402.6×10.7x
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?
I’d go with Vertex Pharmaceuticals. The breadth of its execution across multiple programs simultaneously is rare in biotech, and its cystic fibrosis treatments have become the standard of care for most patients living with the condition. A new pain drug is also gaining commercial traction while CASGEVY is expanding its patient reach. And a recently completed acquisition adds a kidney disease drug awaiting an imminent FDA approval decision, which could open up an entirely new growth chapter.
CRISPR Therapeutics has built something remarkable, with a gene-editing therapy that is approved, commercially successful, and expanding to younger patients. The pipeline is pushing into cardiovascular disease and other areas that could add meaningful new growth engines over time. But CRISPR is still losing a substantial amount of money every quarter, and the investment case depends on continued execution across a pipeline that is still proving itself.
Vertex has already done the hard work of turning a scientific breakthrough into a durable, growing business. CRISPR is earlier in that journey, and the distance between them is still substantial.
Should you buy stock in CRISPR Therapeutics right now?
Before you buy stock in CRISPR Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $389,154!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,406,303!*
Now, it’s worth noting Stock Advisor’s total average return is 947% — a market-crushing outperformance compared to 214% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy.
